Amarin CEO John Thero passes baton to Europe commercial chief as M&A hopes continue to deflate
As Amarin breaks into the European market, John Thero is heading out.
After steering the ship for 7 years, Thero is handing the CEO job to Karim Mikhail, who came on board earlier this year to head the commercialization of Amarin’s fish oil pill in Europe. Mikhail’s appointment is effective Aug. 1, when Thero will officially retire and transition to an advisor role until the end of 2021.
Since joining Amarin in 2009, Thero has been credited for a slate of achievements that gave investors lots to be excited about. Under his watch, Vascepa — the pharmaceutical grade omega-3 fatty acid product first approved in 2012 — was cruised to a positive Phase III data readout despite some controversy, spurring an impressive reduction in risk of cardiovascular events that led to a quick FDA add-on approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.